Literature DB >> 23163631

Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia.

Brian T Fisher1, Jeffrey S Gerber, Kateri H Leckerman, Alix E Seif, Yuan-Shung V Huang, Yimei Li, Tracey Harris, Kari Torp, Rheam Douglas, Ami Shah, Dana Walker, Richard Aplenc.   

Abstract

Antibiotic variation among pediatric oncology patients has not been well-described. Identification of significant variability in antibiotic use within this population would warrant evaluation of its clinical impact. We conducted a retrospective cohort study of newly diagnosed patients with pediatric acute lymophoblastic leukemia (ALL) hospitalized from 1999 to 2009 in 39 freestanding US children's hospitals within the Pediatric Health Information System. Medication use data were obtained for the first 30 days from each patient's index ALL admission date. Antibiotic exposure rates were reported as antibiotic days/1000 hospital days. Unadjusted composite broad-spectrum antibiotic exposure rates varied from 577 to 1628 antibiotic days/1000 hospital days. This wide range of antibiotic exposure was unaffected by adjustment for age, gender, race and days of severe illness (adjusted range: 532-1635 days of antibiotic therapy/1000 hospital days). Antibiotic use for children with newly diagnosed ALL varies widely across children's hospitals and is not explained by demographics or illness severity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23163631      PMCID: PMC3906846          DOI: 10.3109/10428194.2012.750722

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  16 in total

Review 1.  Antimicrobial use and bacterial resistance.

Authors:  S Monroe; R Polk
Journal:  Curr Opin Microbiol       Date:  2000-10       Impact factor: 7.934

2.  The impact of antibiotic use on resistance development and persistence.

Authors:  Teresa M. Barbosa; Stuart B. Levy
Journal:  Drug Resist Updat       Date:  2000-10       Impact factor: 18.500

3.  Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.

Authors:  Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton
Journal:  Clin Infect Dis       Date:  2006-12-13       Impact factor: 9.079

4.  A seven year survey of antibiotic susceptibility and its relationship with usage.

Authors:  R J Courcol; M Pinkas; G R Martin
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

5.  Antibiotic usage in seven community hospitals.

Authors:  W E Scheckler; J V Bennett
Journal:  JAMA       Date:  1970-07-13       Impact factor: 56.272

6.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-02-15       Impact factor: 9.079

7.  Benchmarking risk-adjusted adult antibacterial drug use in 70 US academic medical center hospitals.

Authors:  Ron E Polk; Samuel F Hohmann; Sofia Medvedev; Omar Ibrahim
Journal:  Clin Infect Dis       Date:  2011-10-13       Impact factor: 9.079

8.  Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities.

Authors:  Ronald E Polk; Christopher K Johnson; Donna McClish; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-08-02       Impact factor: 9.079

Review 9.  Quantitative antibiotic use in hospitals: comparison of measurements, literature review, and recommendations for a standard of reporting.

Authors:  S P Kuster; C Ruef; B Ledergerber; A Hintermann; C Deplazes; L Neuber; R Weber
Journal:  Infection       Date:  2008-11-13       Impact factor: 3.553

10.  Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study.

Authors:  Brian T Fisher; Richard Aplenc; Russell Localio; Kateri H Leckerman; Theoklis E Zaoutis
Journal:  Pediatr Infect Dis J       Date:  2009-11       Impact factor: 2.129

View more
  15 in total

1.  Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals.

Authors:  Elizabeth K Goodman; Anne F Reilly; Brian T Fisher; Julie Fitzgerald; Yimei Li; Alix E Seif; Yuan-Shung Huang; Rochelle Bagatell; Richard Aplenc
Journal:  JAMA Pediatr       Date:  2014-10       Impact factor: 16.193

2.  Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation.

Authors:  Caitlin W Elgarten; Staci D Arnold; Yimei Li; Yuan-Shung V Huang; Marcie L Riches; Jeffrey S Gerber; Richard Aplenc; Wael Saber; Brian T Fisher
Journal:  Infect Control Hosp Epidemiol       Date:  2018-05-08       Impact factor: 3.254

3.  Failure to Validate a Multivariable Clinical Prediction Model to Identify Pediatric Intensive Care Unit Patients at High Risk for Candidemia.

Authors:  Brian T Fisher; Rachael K Ross; Emmanuel Roilides; Debra L Palazzi; Mark J Abzug; Jill A Hoffman; David M Berman; Priya A Prasad; A Russell Localio; William J Steinbach; Lambrini Vogiatzi; Ankhi Dutta; Theoklis E Zaoutis
Journal:  J Pediatric Infect Dis Soc       Date:  2015-04-29       Impact factor: 3.164

4.  Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States.

Authors:  Elizabeth G Salazar; Yimei Li; Brian T Fisher; Susan R Rheingold; Julie Fitzgerald; Alix E Seif; Yuan-Shung Huang; Rochelle Bagatell; Richard Aplenc
Journal:  Br J Haematol       Date:  2016-05-10       Impact factor: 6.998

5.  Variation in Risk of Hospital-Onset Clostridium difficile Infection Across β-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia.

Authors:  Brian T Fisher; Julia Shaklee Sammons; Yimei Li; Peter de Blank; Alix E Seif; Yuan-Shung Huang; Marko Kavcic; Sarah Klieger; Tracey Harris; Kari Torp; Douglas Rheam; Ami Shah; Richard Aplenc
Journal:  J Pediatric Infect Dis Soc       Date:  2014-02-16       Impact factor: 3.164

6.  Variability in Antifungal and Antiviral Use in Hospitalized Children.

Authors:  Jennifer L Goldman; Rachael K Ross; Brian R Lee; Jason G Newland; Adam L Hersh; Matthew P Kronman; Jeffrey S Gerber
Journal:  Infect Control Hosp Epidemiol       Date:  2017-03-15       Impact factor: 3.254

7.  Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia.

Authors:  Mallorie B Heneghan; Susan R Rheingold; Yimei Li; Alix E Seif; Yuan-Shung Huang; Lisa McLeod; Lawrence Wells; Brian T Fisher; Richard Aplenc
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-01-04

8.  Supportive care medications coinciding with chemotherapy among children with hematologic malignancy.

Authors:  Eman Biltaji; Elena Y Enioutina; Venkata Yellepeddi; Joseph E Rower; Catherine M T Sherwin; Robert M Ward; Richard S Lemons; Jonathan E Constance
Journal:  Leuk Lymphoma       Date:  2020-04-07

9.  The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.

Authors:  Rebecca Citrin; Kelly D Getz; Yimei Li; Yuan-Shung Huang; Joseph P Horowitz; Alix E Seif; Brian T Fisher; Richard Aplenc
Journal:  Br J Haematol       Date:  2018-04-02       Impact factor: 6.998

10.  Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Grace E Lee; Brian T Fisher; Rui Xiao; Susan E Coffin; Kristen Feemster; Alix E Seif; Rochelle Bagatell; Yimei Li; Yuan-Shung V Huang; Richard Aplenc
Journal:  J Pediatric Infect Dis Soc       Date:  2014-07-22       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.